TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2472994

Group type: EXPERIMENTAL
Intervention: Glucagon and insulin therapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 362955

Group type: EXPERIMENTAL
Intervention: Levamisole (50-150 mg)
Number of subjects: 1734

Group type: COMPARATOR
Intervention: Pyrantel
Number of subjects: 1734

Group type: COMPARATOR
Intervention: Piperazine
Number of subjects: 1734

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1734

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 1734
Study: 31757095

Group type: EXPERIMENTAL
Intervention: Marine n-3 PUFA (three 1 g capsules containing 460 mg/g EPA and 380 mg/g DHA) for 44 weeks
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control (olive oil) for 44 weeks
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Marine n-3 PUFA
Number of subjects: 132
Study: 28440817

Group type: EXPERIMENTAL
Intervention: Sulpiride (800 mg p.o.)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 25922903

Group type: COMPARATOR
Intervention: Placebo nitrite cream and placebo citric acid cream applied twice daily
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Low-dose treatment (sodium nitrite, 3%, with citric acid, 4.5%, creams applied twice daily)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Middle-dose treatment (sodium nitrite, 6%, with citric acid, 9%, creams applied once daily at night, with placebo applied in the morning)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: High-dose treatment (sodium nitrite, 6%, with citric acid, 9%, creams applied twice daily)
Number of subjects: 299
Study: 24607004

Group type: EXPERIMENTAL
Intervention: High Dose (HD) - 5×10(8) TCID50 of modified vaccinia Ankara
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard Dose (SD) - 1×10(8) TCID50 of modified vaccinia Ankara (2 doses)
Number of subjects: 90
Study: 22401479

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 19365118

Group type: EXPERIMENTAL
Intervention: Experimental liquid dentifrice (ELD), 1,100 ppm F, pH 7.0
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Experimental liquid dentifrice (ELD), 1,100 ppm F, pH 4.5
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Experimental liquid dentifrice (ELD), 550 ppm F, pH 4.5
Number of subjects: 2

Group type: COMPARATOR
Intervention: Commercial toothpaste, 1,100 ppm F, pH 7.0
Number of subjects: 2
Study: 18074029

Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg po bid
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg po bid
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Oseltamivir carboxylate (metabolite)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combination of amantadine and oseltamivir
Number of subjects: 17
Study: 15576702

Group type: EXPERIMENTAL
Intervention: High fidelity simulation based team training (8 hour intensive experience in an ED simulator with three scenarios of graduated difficulty)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Didactic training in the Emergency Team Coordination Course (ETCC) with no additional simulation training
Number of subjects: 0
Study: 11170731

Group type: EXPERIMENTAL
Intervention: Dysport (botulinum neurotoxin type A) diluted to a final concentration of 50 U/ml, low-dose treatment cut by approximately 70%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recommended higher doses of Dysport
Number of subjects: 0
Study: 10181022

Group type: EXPERIMENTAL
Intervention: Observed fidelity (based on dual observation)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Rapport (measured during teacher observations)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Post-implementation interview measures
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Teacher self-report questionnaire
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Implementation variables (overall)
Number of subjects: 37
Study: 8026092

Group type: EXPERIMENTAL
Intervention: Topical aural antibiotic therapy (7-day course)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Topical aural antibiotic therapy administered by someone other than the patient
Number of subjects: 50
Study: 2783481

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation at acupuncture points (30‐Hz current applied to 'spleen 6' and 'liver 3')
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo condition (equipment attached but not activated)
Number of subjects: 20
Study: 960794

Group type: EXPERIMENTAL
Intervention: Coffee
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Caffeine solution
Number of subjects: 9

Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hot water
Number of subjects: 9
Study: 31498783

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg 10-minutes before induction and 0.5 μg/kg/hour maintenance infusion until end of operation)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (normal saline of same amount and at same rate)
Number of subjects: 40
Study: 26924599

Group type: COMPARATOR
Intervention: Iron + Folic Acid (IFA)
Number of subjects: 1320

Group type: COMPARATOR
Intervention: Micronutrient Mix (MMN)
Number of subjects: 1320

Group type: COMPARATOR
Intervention: Small-Quantity Lipid-Based Nutrient Supplements (SQ-LNS)
Number of subjects: 1320
Study: 26264648

Group type: EXPERIMENTAL
Intervention: Group cognitive behavior therapy (gCBT)
Number of subjects: 190
Study: 23118022

Group type: EXPERIMENTAL
Intervention: Antidopaminergic treatment (aripiprazole, haloperidol, or reserpine)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 22153396

Group type: EXPERIMENTAL
Intervention: Strabismus surgery performed for 53 children
Number of subjects: 342
Study: 19932779

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Combination therapy (telmisartan + ramipril)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 287
Study: 17684878

Group type: EXPERIMENTAL
Intervention: 15 mg of hyperbaric ropivacaine with 0.1 mg of preservative-free morphine and 0.01 mg fentanyl
Number of subjects: 66

Group type: COMPARATOR
Intervention: 11.25 mg of hyperbaric bupivacaine with 0.1 mg of preservative-free morphine and 0.01 mg fentanyl
Number of subjects: 66
Study: 15616954

Group type: EXPERIMENTAL
Intervention: Wound dressing
Number of subjects: 451

Group type: COMPARATOR
Intervention: No dressing (exposed wounds)
Number of subjects: 451
Study: 11238483

Group type: EXPERIMENTAL
Intervention: 50 g protein in the form of very lean beef
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study: 9669811

Group type: EXPERIMENTAL
Intervention: Hybrid chemotherapy (HYB) - CAV/PVP, 3-drug CAV on Day 1 and 2-drug PVP on Day 8, repeated every 4 weeks for up to 6 cycles.
Number of subjects: 129

Group type: COMPARATOR
Intervention: Sequential chemotherapy (SEQ) - CAV followed by PVP, 3 cycles each every 4 weeks, delivered on Days 1 and 8.
Number of subjects: 129
Study: 7950884

Group type: EXPERIMENTAL
Intervention: Education programme for cancer prevention and early detection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study: 3261647

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 468

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Surgical treatment (ejection fractions 0.30 to 0.49)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Medical treatment (ejection fractions > 0.69)
Number of subjects: 468
Study: 31910451

Group type: EXPERIMENTAL
Intervention: Classical music (Bach and Bushido)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Traditional training methods
Number of subjects: 24
Study: 31665005

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Systemic therapies
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Localised disease
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Advanced disease with no treatment
Number of subjects: 777
Study: 30189462

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral strategies (CBS) intervention
Number of subjects: 164

Group type: COMPARATOR
Intervention: Cancer education recordings (attention-control)
Number of subjects: 164
Study: 27225598

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation plus tablet (tablet group)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Pulmonary rehabilitation only (control group)
Number of subjects: 115
Study: 24114194

Group type: EXPERIMENTAL
Intervention: Sustained release (SR) formulations of ONO-5334
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sustained release (SR) tablets of ONO-5334
Number of subjects: 0
Study: 22797880

Group type: EXPERIMENTAL
Intervention: Oral pregabalin, 75 mg q12 h for five consecutive days starting the night before surgery
Number of subjects: 110

Group type: COMPARATOR
Intervention: Identical placebos
Number of subjects: 110
Study: 19485587

Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy (MST)
Number of subjects: 127
Study: 17805093

Group type: EXPERIMENTAL
Intervention: Live high-train low (LH+TL) altitude training at a natural elevation of 2000-2500 m for >or=4 weeks for >or=22 hours per day.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulated LH+TL devices (e.g., nitrogen apartments, hypoxic tents, hypoxicator devices)
Number of subjects: 0
Study: 15154878

Group type: EXPERIMENTAL
Intervention: Etidronate 200 mg orally before sleep on dialysis days (3 times per week)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no etidronate treatment)
Number of subjects: 18
Study: 11666124

Group type: EXPERIMENTAL
Intervention: Total triterpenic fraction of Centella asiatica (TTFCA) 60 mg twice daily for 6 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: COMPARATOR
Intervention: No treatment (second control group)
Number of subjects: 50
Study: 9678378

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted resection
Number of subjects: 16

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 16
Study: 7990345

Group type: EXPERIMENTAL
Intervention: Induracin, prolonged nicotinic acid
Number of subjects: 31
Study: 3058442

Group type: EXPERIMENTAL
Intervention: Domperidone (20 mg before meals and at bedtime for six weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (oral for six weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31668393

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) bolus
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: GH infusion
Number of subjects: 9

Group type: COMPARATOR
Intervention: GH-receptor antagonist (pegvisomant)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fasting (36-hour)
Number of subjects: 9
Study: 28937255

Group type: EXPERIMENTAL
Intervention: Oral administration of whey proteins (OWIST)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 16
Study: 26525617

Group type: EXPERIMENTAL
Intervention: Low calorie diet therapy (LCDT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard antihypertensive treatment
Number of subjects: 22
Study: 23624884

Group type: EXPERIMENTAL
Intervention: Fecal incontinence (FI) experiences in people with IBD
Number of subjects: 3264

Group type: EXPERIMENTAL
Intervention: Coping strategies for IBD-related FI
Number of subjects: 3264

Group type: EXPERIMENTAL
Intervention: Emotional and psychological impact of IBD-related FI
Number of subjects: 3264

Group type: EXPERIMENTAL
Intervention: Access to professional support for IBD-related FI
Number of subjects: 3264
Study: 21748448

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 100

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 100
Study: 19141576

Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg daily (with adjustments to 40 mg or 120 mg as needed)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Febuxostat treatment
Number of subjects: 116
Study: 17583188

Group type: EXPERIMENTAL
Intervention: Perindopril/Indapamide combination (Per 2 mg/Ind 0.625 mg) for 3-6 months
Number of subjects: 17938
Study: 14999211

Group type: EXPERIMENTAL
Intervention: Wiktor stent implantation
Number of subjects: 221

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 221
Study: 11174052

Group type: EXPERIMENTAL
Intervention: riluzole 150 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 9296037

Group type: EXPERIMENTAL
Intervention: Combination of malocid-sulfadiazine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Clindamycin subconjunctivally
Number of subjects: 43
Study: 8320004

Group type: EXPERIMENTAL
Intervention: Concept 45 degrees toothbrush with the Bass technique
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Concept 45 degrees toothbrush with the roll technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard conventional toothbrush with the roll technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard conventional toothbrush with the Bass technique
Number of subjects: 100
Study: 3577821

Group type: COMPARATOR
Intervention: Adenosine 0.07 mg kg‐1 min‐1 following saline
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Adenosine 0.005 mg kg‐1 min‐1 following dipyridamole
Number of subjects: 8

Group type: COMPARATOR
Intervention: Adenosine 0.08-0.09 mg kg‐1 min‐1 following saline
Number of subjects: 8
Study: 28508330

Group type: EXPERIMENTAL
Intervention: Guided intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-Directed
Number of subjects: 0
Study: 27317506

Group type: EXPERIMENTAL
Intervention: Self-motivated eHealth lifestyle intervention
Number of subjects: 2972
Study: 24045438

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS) spray
Number of subjects: 130

Group type: COMPARATOR
Intervention: Mechanical stapling (MS)
Number of subjects: 130
Study: 23391132

Group type: EXPERIMENTAL
Intervention: Situated Optimal Adherence Intervention Estonia (sOAI Estonia) which includes Next‐Step Counseling (NSC) and Information‐Motivation‐Behavioral Skills (IMB) Model approach.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 0
Study: 20884422

Group type: EXPERIMENTAL
Intervention: Intravenous enoxaparin 0.75 mg/kg
Number of subjects: 876

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: Intravenous enoxaparin 0.75 mg/kg in patients with ACS
Number of subjects: 876

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) in patients with ACS
Number of subjects: 876
Study: 17329124

Group type: EXPERIMENTAL
Intervention: FM strength training protocol
Number of subjects: 20

Group type: COMPARATOR
Intervention: CM strength training protocol
Number of subjects: 20
Study: 16635085

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 320/9 microg, two inhalations bd (1280/36 microg/day)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Budesonide plus formoterol via separate inhalers
Number of subjects: 456

Group type: COMPARATOR
Intervention: Budesonide
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Budesonide plus formoterol
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 456
Study: 12559642

Group type: EXPERIMENTAL
Intervention: Interim analysis of a new drug for autoimmune disease
Number of subjects: 0
Study: 11570837

Group type: EXPERIMENTAL
Intervention: Direct contact group
Number of subjects: 986

Group type: COMPARATOR
Intervention: PHT group
Number of subjects: 986

Group type: COMPARATOR
Intervention: Program group
Number of subjects: 986
Study: 9127653

Group type: EXPERIMENTAL
Intervention: PCEA with pethidine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PCEA with fentanyl
Number of subjects: 80

Group type: COMPARATOR
Intervention: PCIA with pethidine
Number of subjects: 80

Group type: COMPARATOR
Intervention: PCIA with fentanyl
Number of subjects: 80
Study: 7692189

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) at 10.5 +/- 1.2 micrograms/kg per day
Number of subjects: 23
Study: 3092696

Group type: EXPERIMENTAL
Intervention: Isoflurane (I)
Number of subjects: 70
Study: 30558653

Group type: EXPERIMENTAL
Intervention: Nurse‐implemented, goal‐directed, comfort algorithm
Number of subjects: 2800
Study: 26277877

Group type: EXPERIMENTAL
Intervention: Ultrasound-indicated cerclage
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control (no cerclage)
Number of subjects: 301
Study: 24256166

Group type: EXPERIMENTAL
Intervention: 1.5 μg Ni/week
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 22547727

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted D2 distal gastrectomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Open distal D2 gastrectomy
Number of subjects: 80
Study: 20492055

Group type: EXPERIMENTAL
Intervention: Cluster level models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual patient level models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual level data models
Number of subjects: 0
Study: 19193339

Group type: COMPARATOR
Intervention: Duloxetine 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg
Number of subjects: 0
Study: 16514812

Group type: EXPERIMENTAL
Intervention: Lisinopril administration
Number of subjects: 94

Group type: COMPARATOR
Intervention: Captopril administration
Number of subjects: 94
Study: 11165527

Group type: EXPERIMENTAL
Intervention: Active rTMS to the supplementary motor area (SMA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham rTMS to the supplementary motor area (SMA)
Number of subjects: 10
Study: 9625099

Group type: EXPERIMENTAL
Intervention: Elevated AGP (> or = 1 g/L)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Elevated CRP (> or = 5 mg/L)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Diarrhea and elevated AGP
Number of subjects: 234

Group type: COMPARATOR
Intervention: Diarrhea only
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Illness in the previous week with elevated CRP or AGP
Number of subjects: 234
Study: 8170176

Group type: EXPERIMENTAL
Intervention: Aspirin preoperatively
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Heparin followed by warfarin sodium
Number of subjects: 64

Group type: COMPARATOR
Intervention: TE group (Thromboembolism)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Non-TE group (No Thromboembolism)
Number of subjects: 64
Study: 3354812

Group type: EXPERIMENTAL
Intervention: 16-gauge Tuohy needle
Number of subjects: 685

Group type: COMPARATOR
Intervention: 18-gauge Tuohy needle
Number of subjects: 685
Study: 1331724

Group type: EXPERIMENTAL
Intervention: Oatbran (60 g per day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Wheatbran (equivalent amount of fibre)
Number of subjects: 37
Study: 354331

Group type: EXPERIMENTAL
Intervention: Fluspirilene
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluphenazine decanoate
Number of subjects: 50
Study: 30597302

Group type: EXPERIMENTAL
Intervention: Six-week focused meditation training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study: 27743337

Group type: EXPERIMENTAL
Intervention: Health education intervention based on the Health Belief Model (HBM)
Number of subjects: 201
Study: 23837502

Group type: EXPERIMENTAL
Intervention: Submerged implant placement
Number of subjects: 106

Group type: COMPARATOR
Intervention: Transmucosal implant placement
Number of subjects: 106
Study: 24409075

Group type: EXPERIMENTAL
Intervention: Nedaplatin (NDP) 80‐100 mg/m² iv on day 1 + leucovorin (CF) 100 mg/m² iv on days 1‐5 + 5‐fluorouracil (5‐FU) 500 mg/m² iv on days 1‐5
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Nedaplatin (NDP)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Cisplatin (DDP)
Number of subjects: 68
Study: 22151509

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (the pill)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Contraceptive ring
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUD
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Patch
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Injectable
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Copper IUD
Number of subjects: 468
Study: 19393409

Group type: EXPERIMENTAL
Intervention: Silver nitrate cautery followed by antiseptic cream for 4 weeks
Number of subjects: 109

Group type: COMPARATOR
Intervention: Sham cautery followed by antiseptic cream for 4 weeks
Number of subjects: 109
Study: 17370660

Group type: EXPERIMENTAL
Intervention: Telescopic crowns on two endosseous implants
Number of subjects: 22

Group type: COMPARATOR
Intervention: Telescopic crowns on maxillary canines
Number of subjects: 22
Study: 15331202

Group type: EXPERIMENTAL
Intervention: Oolong tea (1000 ml)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 22
Study: 11439796

Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway (ILMA) with lightwand
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intubating laryngeal mask airway (ILMA) alone
Number of subjects: 100
Study: 9625830

Group type: EXPERIMENTAL
Intervention: mRNA index measurement in proliferating cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mRNA index measurement in cancer cells (gastric cancer, colon cancer, bile duct cancer, gallbladder cancer)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mRNA index measurement in PBM patients with precancerous lesions
Number of subjects: 0
Study: 8143398

Group type: EXPERIMENTAL
Intervention: Inhaled marijuana smoke (1 marijuana cigarette containing 1.54% delta 9‐tetrahydrocannabinol)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (normal volunteers)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inhaled marijuana smoke
Number of subjects: 20
Study: 2895664

Group type: EXPERIMENTAL
Intervention: sublingual lormetazepam 2.5 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: i.v. diazepam 10 mg
Number of subjects: 40